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Rationale: Long-term clinical implications of beta-blockade in obstructive airway
diseases remains controversial. We investigated if within the first 5 years of treatment
patients with heart failure and obstructive airway diseases using non β1-adrenoreceptor
selective beta-blockers have an increased risk of being hospitalized for all-causes, heart
failure, and chronic obstructive pulmonary disease (COPD) when compared to patient
using selective beta-blockers.
Methods: Carvedilol users were propensity matched 1:1 for co-treatments, age,
gender, and year of inclusion in the cohort with metoprolol/bisoprolol/nebivolol users.
Cox proportional hazard regression model was used to compare all causes, COPD, and
heart failure hospitalization or the beta-blocker discontinuation between cohorts. For
statistically significant associations, we computed the rate difference and the attributable
risk.
Results: Overall, 11,844 patients out of the 51,214 (23.1%) were exposed to carvedilol
and 39,370 (76.9%) to metoprolol/bisoprolol/nebivolol. Carvedilol users had a higher
hazard for heart failure hospitalization (HR 1.29; 95% Confidence Interval [CI] 1.18–
1.40) with 106 (95%CI 76–134; p-value < 0.001) additional cases of heart failure
hospitalization per 10000 person-years if compared to metoprolol/bisoprolol/nebivolol
users. In all, 26.8% (95%CI 22.5–30.9%; p-value < 0.001) of heart failure
hospitalizations in the study population could be attributed to being exposed
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to carvedilol. Carvedilol users had a higher hazard (HR 1.06; 95%CI 1.02–
1.10) of discontinuing the pharmacological treatment with 131 (95%CI 62–201;
p-value < 0.001) additional cases of beta-blocker discontinuation per 10000
person-years metoprolol/bisoprolol/nebivolol users. In all, 6.5% (95%CI 3.9–9.0%;
p-value < 0.001) of beta-blocker discontinuation could be attributed to being exposed
to carvedilol.
Conclusion: On long-term follow-up period, carvedilol was associated with a
higher risk of heart failure hospitalization and discontinuation if compared to
metoprolol/bisoprolol/nebivolol users among patients with heart failure and obstructive
airway diseases.
Keywords: clinical epidemiology, obstructive respiratory diseases, humans, pharmacoepidemiology,
pharmacology, beta-blockers, heart failure
INTRODUCTION
Beta-blockers are able to reduce mortality in patients with
concurrent heart failure and respiratory diseases and, therefore,
the co-existence of both diseases should not discourage the
clinicians from using these drugs (Rutten et al., 2010; Short
et al., 2011; Du et al., 2014; Lim et al., 2017). While beta-
blockade is clinically useful for heart failure, it could induce
bronchoconstriction and worsen lung function in patients with
asthma or chronic obstructive pulmonary disease (COPD)
(Grieco and Pierson, 2017). Among beta-blockers approved
for heart failure, those less selective for β1-adrenoreceptor,
such as carvedilol, were associated with a higher risk of
obstructive airway diseases exacerbations (van der Woude et al.,
2005; Hawkins et al., 2009; Short et al., 2011, 2014). In fact,
European Society of Cardiology (ESC) and Global Initiative for
Chronic Obstructive Lung Disease (GOLD) clinical guidelines
recommended more selective β1-adrenoreceptor antagonist in
patients with concurrent heart failure and respiratory diseases
(i.e., COPD and asthma) (Dickstein et al., 2008, 2010; McMurray
et al., 2012; Ponikowski et al., 2016). However, the majority of
studies comparing β1-selective and non-selective beta-blockers
in patients with heart failure and concurrent respiratory diseases
focused on short-term follow-up period post beta-blockers
initiation and only a few studies provided outcomes of public
health interest (Salpeter et al., 2002; Hawkins et al., 2009;
Jabbour et al., 2010; Rutten et al., 2010; Dungen et al., 2011;
Lainscak et al., 2011; Etminan et al., 2012; Kubota et al., 2015;
Ponikowski et al., 2016; Sessa et al., 2017a). Studies investigating
clinical implications of beta-blockade on a long-term follow-up
period are necessary, considering that the clinical implications
observable during the start of beta-blocker initiation/up-titration
do not necessarily reflect those occurring in the later phases
of treatment (Baker and Wilcox, 2017). The first period of
treatment with beta-blockers represents the most critical for
bronchoconstriction because patients are up titrated to receive
the optimal dosage of beta-blocker (Grieco and Pierson, 2017). In
the later phases, when patients are symptomatically stable, there
is a tendency to preserve a stable posological schema (Dickstein
et al., 2008, 2010; McMurray et al., 2012; Ponikowski et al., 2016).
Moreover, patients with asthma or COPD could have been
exposed for a long period to β2-adrenoreceptor agonist, a
phenomenon promoting the development of β2-adrenoreceptor
desensitization in the respiratory system (Hausdorff et al., 1990;
Lohse et al., 1996; Chong et al., 2003). Consequently, patients
could be less sensitive to acute beta-blockade effects in the
respiratory system due to both desensitization mechanisms
of β2-adrenoreceptor and to the competitive binding of β2-
adrenoreceptor agonist that are typically co-administrated in
patients having both diseases. However, on long-term, the
prolonged β2-adrenoreceptor antagonism performed by beta-
blockers less selective for β1-adrenoreceptor receptors can
alter pulmonary compliance leading to dynamic hyperinflation
even in presence of β2-adrenoreceptor agonists (Jabbal and
Lipworth, 2018). Dynamic hyperinflation, in turn, apart from
negative respiratory outcomes, can promote impaired ventricular
filling and low cardiac output along with a reduction of
intrathoracic blood volume and pulmonary vein dimensions,
all phenomenon that can promote decompensation of heart
failure (Jorgensen et al., 2007; Watz et al., 2010; Barr et al.,
2012; Stone et al., 2016; Watz, 2016). In this clinical scenario,
β1-adrenoreceptor selectivity of beta-blockers may still play
a key role for the recrudescence of both heart failure and
obstructive airway diseases symptoms. To provide further insight
on this aspect we investigated if patients with heart failure and
concurrent COPD or asthma with long-term exposure to low β1-
adrenoreceptor selectivity beta-blockers have an increased risk
of being hospitalized for all-causes, heart failure, and obstructive
airway diseases compared to non-selective beta-blockers.
MATERIALS AND METHODS
Data Sources
Caserta Local Health Unit administrative databases were used
as data sources. For reimbursement purposes, these databases
contain information on age, gender, date of birth, and death,
drugs redeemed/supplied and hospitalization occurred for more
than 1,000,000 citizens living in the catchment area of Caserta
(Campania Region, Italy). For each redeemed prescription, we
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retrieved information on the active ingredient, the Anatomical
Therapeutic Chemical (ATC) classification code, the quantity,
and the dispensing date. According to the Italian law for
confidentiality data, in each administrative database, critical
information for privacy are encrypted and a unique anonymized
identifier guarantee the linkage among these databases.
Study Population
The study population was composed of patients that redeemed
carvedilol, metoprolol, bisoprolol or nebivolol prescriptions
along with drugs for obstructive airway diseases (ATC
R03) from December 31, 2010 to September 30, 2017.
Given the different cardioselectivity of aforementioned β-
blockers, which are all indicated for heart failure, patients
were divided into two cohorts, those exposed to carvedilol
(lower β1-adrenoreceptor selectivity) and those exposed to
metoprolol/bisoprolol/nebivolol (higher β1-adrenoreceptor
selectivity). We believe that by including patients co-exposed
to reimbursed drugs for obstructive airway diseases (ATC R03)
it is possible to identify both patients with asthma and COPD,
however, mainly patients with COPD. In fact, Caserta Local
Health Unit pharmaceutical administrative databases contain
redeemed prescriptions for drugs that are reimbursed by the
Italian Healthcare system. Those having ATC code R03 include
aclidinium, beclomethasone, beclomethasone/formoterol,
budesonide, budesonide/formoterol, fluticasone, formoterol,
glycopyrronium, indacaterol, indacaterol/glycopyrronium,
ipratropium bromide, nedocromil, salbutamol, salmeterol,
salmeterol/fluticasone, theophylline, and tiotropium (Italian
Medicine Agency, 2017). While some of these drugs are indicated
for both asthma and COPD, the use of beta-blockers in asthma
is contraindicated in both summaries of product characteristics
and current clinical guidelines (Bousquet et al., 2007; Dickstein
et al., 2008, 2010; McMurray et al., 2012; Ponikowski et al., 2016).
Follow-Up Period
The first date of co-exposure to beta-blocker and R03 drugs was
used as the index date for each patient. Patients were followed
through Caserta Local Health Unit administrative databases from
index date to outcome or censoring at death or at the end of
follow-up on September 30, 2017.
Outcomes
The first, second and third primary outcomes were the hazard
ratio (HR) of being hospitalized for all causes, COPD and heart
failure within 60 months from the index date for carvedilol users
vs. metoprolol/bisoprolol/nebivolol users. The HR of discontinue
the beta-blocker within 60 months from the index date for
carvedilol users vs. metoprolol/bisoprolol/nebivolol users was
also investigated.
Study Covariates
Age, gender, and co-treatments were obtained at index date.
Statistical Analyses
At index date, baseline characteristics of men and women were
compared using the t-tests for continuous variables and χ2 test
for categorical variables. To estimate the period of treatment
with carvedilol or metoprolol/bisoprolol/nebivolol, the ongoing
exposure was calculated for each individual by dividing the
number of posological units dispensed by the estimated average
dosage for the heart failure indication as described elsewhere
(Andersson et al., 2012). Prior to data analyses, at index date,
we matched patients exposed to carvedilol with those exposed
to metoprolol/bisoprolol/nebivolol with a 1:1 match for our
study covariates using the neighborhood matching algorithm
(Austin, 2014). Histograms of propensity score were plotted
prior and after matching to examine the effectiveness of the
matching algorithm in balancing the covariates between the two
cohorts. For the matched cohorts, cumulative incidence curves
were generated to compare cumulative incidence for the study
outcomes. Gray’s test was used to evaluate the hypotheses that
cause-specific cumulative functions were equal. Cox proportional
hazard regression model with only outcome and exposure was
used to compare the hazard of all causes, COPD, and heart failure
hospitalization or beta-blocker discontinuation between the two
cohorts. For statistically significant associations, we computed
the rate difference and the attributable risk percentage for the
outcome under investigation for carvedilol users as opposed
to metoprolol/bisoprolol/nebivolol users as described elsewhere
(Davis et al., 2003; Xu et al., 2010). All analyses were based on
intention-to-treat approach and used a statistically significant
level of p< 0.05 (2-sided).
Compliance With Ethical Standards
In Italy, retrospective register-based studies do not require
informed consent or ethical approval (Agenzia Italiana del
Farmaco, 2008).
RESULTS
In Caserta Local Health Unit (Italy) administrative databases, we
identified 51,214 patients exposed to β-blockers for heart failure
(carvedilol, metoprolol, bisoprolol and nebivolol) concurrently
with obstructive airway diseases drugs (ATC R03). Out of the
51,214 patients, 11,844 (23.1%) were exposed to carvedilol and
39,370 (76.9%) to metoprolol/bisoprolol/nebivolol. By matching
1:1 carvedilol users with metoprolol/bisoprolol/nebivolol users,
we obtained the study population of 23,688 patients (Table 1).
The matching was successful and is presented in Table 1
and Supplementary Figure 1. Patients exposed to carvedilol
were followed for 29,828 person-years, while those exposed
to metoprolol/bisoprolol/nebivolol for 31,270 person-years in
Caserta Local Health Unit administrative databases.
Comparison of All-Cause, Chronic
Obstructive Pulmonary Disease, and
Heart Failure Hospitalization Between
Carvedilol and
Metoprolol/Nebivolol/Bisoprolol Users
All-causes, COPD and heart failure cumulative incidence
curves for carvedilol and metoprolol/bisoprolol/nebivolol
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TABLE 1 | Demographic characteristics and concurrent pharmacological treatments of patients exposed to carvedilol or metoprolol/bisoprolol/nebivolol in the period









Age mean (SD) 74.4 (12.6) 74.2 (13.4) 74.3 (13.0) 0.188
Gender Male 5858 (49.5) 5801 (49.0) 11659 (49.2) 0.466
Year of inclusion 2011 3131 (26.4) 2968 (25.1) 6099 (25.7)
2012 2916 (24.6) 2959 (25.0) 5875 (24.8)
2013 2067 (17.5) 2044 (17.3) 4111 (17.4)
2014 1259 (10.6) 1350 (11.4) 2609 (11.0)
2015 1146 (9.7) 1289 (10.9) 2435 (10.3)
2016 906 (7.6) 864 (7.3) 1770 (7.5)
2017 419 (3.5) 370 (3.1) 789 (3.3) 0.126
Angiotensin-converting enzyme
inhibitors
N (%) 4211 (35.6) 1321 (36.5) 8532 (36.0) 0.264
Hydroxymethylglutaryl-CoA
reductase inhibitors
N (%) 894 (7.5) 878 (7.4) 1772 (7.5) 0.711
Angiotensin II Receptor
Blockers
N (%) 2726 (23.0) 2658 (22.4) 5384 (22.7) 0.139
Calcium channel blockers N (%) 3075 (26.0) 3014 (25.4) 6089 (25.7) 0.372
Vitamin K antagonist N (%) 941 (7.9) 958 (8.1) 1899 (8.0) 0.701
Low-dose acetylsalicylic acid N (%) 4498 (38.0) 4460 (37.7) 8958 (37.8) 0.620
Loop diuretics N (%) 4191 (35.4) 4268 (36.0) 8459 (35.7) 0.302
Potassium-sparing diuretics N (%) 1827 (15.4) 1852 (15.6) 3679 (15.5) 0.666
Sodium-Channel Blockers
(Class I Antiarrhythmics)∗
N (%) 252 (2.1) 260 (2.2) 512 (2.2) 0.754
Potassium-Channel Blockers
(Class III Antiarrhythmics)∗
N (%) 580 (4.9) 595 (5.0) 1175 (5.0) 0.675
Organic nitrates N (%) 1722 (14.5) 1785 (15.1) 3507 (14.8) 0.256
Anticholinergic long-acting N (%) 2153 (18.2) 2126 (18.0) 4279 (18.1) 0.440
Anticholinergic short-acting N (%) 566 (4.8) 582 (4.9) 1148 (4.8) 0.649
Beta 2 agonist + anticholinergic N (%)
Beta 2 agonist long-acting –
inhalers
N (%) 584 (4.9) 611 (5.2) 1195 (5.0) 0.440
Beta 2 agonist short-acting –
inhalers
N (%) 876 (7.4) 950 (8.0) 1826 (7.7) 0.075
Glucorticoid + beta 2 agonist N (%) 7995 (67.5) 7950 (67.1) 15945 (67.3) 0.542
Glucorticoids - inhalers N (%) 6715 (56.7) 6651 (56.2) 13366 (56.4) 0.409
Mast-cell stabilizer N (%) 1745 (14.7) 1819 (15.4) 3564 (15.0) 0.184
Leukotriene receptor antagonist N (%) 193 (1.6) 196 (1.7) 389 (1.6) 0.918
Phosphodiesterase inhibitors N (%) 1557 (13.1) 1606 (13.6) 3163 (13.4) 0.359
∗According to Vaughan-Williams classification of antiarrhythmic drugs (Vaughan Williams, 1984).
users are provided in Figures 1–3, respectively. Within
60 months from the index date, no statistically significant
differences were found for the hazard of being hospitalized for
all causes (HR 1.00; 95% confidence interval (CI) 0.96–1.04)
or COPD (HR 1.04; 95%CI 0.91–1.19) between carvedilol
and metoprolol/bisoprolol/nebivolol users. For heart failure
hospitalization, carvedilol users had a higher hazard compared
with metoprolol, bisoprolol, and nebivolol users (HR 1.29;
95%CI 1.18–1.40). Additionally, within the same follow-up
period, carvedilol users had a higher hazard (HR 1.06; 95%CI
1.02–1.10) of discontinuing the beta-blocker if compared
to patients exposed to metoprolol/bisoprolol/nebivolol
(Figure 4).
Rate Difference and Attributable Risk
Percentage of Heart Failure
Hospitalization and Treatment
Discontinuation for Carvedilol
Users as Opposed to
Metoprolol/Bisoprolol/Nebivolol
By computing the rate difference between the two cohorts,
it was found that patients exposed to carvedilol had 106
(95%CI 76–134; p-value < 0.001) additional cases of heart
failure hospitalization per 10,000 person-years when compared
to patients exposed to metoprolol/bisoprolol/nebivolol. In
all, 26.8% (95%CI 22.5–30.9%; p-value < 0.001) of heart
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FIGURE 1 | Cumulative incidence curves for all-cause hospitalization in
carvedilol users vs. metoprolol, bisoprolol, and nebivolol users.
FIGURE 2 | Cumulative incidence curves for COPD hospitalization in
carvedilol users vs. metoprolol, bisoprolol, and nebivolol users.
failure hospitalizations were attributed to carvedilol exposure.
Patients exposed to carvedilol had 131 (95%CI 62–201;
p-value< 0.001) additional cases of beta-blocker discontinuation
per 10,000 person-years when compared to patients exposed
to metoprolol/bisoprolol/nebivolol. In all, 6.5% (95%CI 3.9–
9.0%; p-value < 0.001) of beta-blocker discontinuation could be
attributed to being exposed to carvedilol.
DISCUSSION
This study provided evidence on the impact of long-term
beta-blocker administration for all causes, COPD, heart
failure hospitalization or beta-blocker discontinuation
within the first 60 months of treatment for carvedilol and
metoprolol/bisoprolol/nebivolol users co-treated with drugs for
COPD or asthma. On a long-term follow-up period, carvedilol
use was associated with an increased hazard of heart failure
hospitalization while no statistically significant differences were
FIGURE 3 | Cumulative incidence curves for heart failure hospitalization in
carvedilol users vs. metoprolol, bisoprolol, and nebivolol users.
FIGURE 4 | Cumulative incidence curves for beta-blocker discontinuation in
carvedilol users vs. metoprolol, bisoprolol, and nebivolol users.
observed for all-cause and COPD hospitalizations. Additionally,
carvedilol users were found to discontinue beta-blocker
treatment more than metoprolol/bisoprolol/nebivolol users.
Our results are in line with previous studies investigating this
topic (Salpeter et al., 2002; Jabbour et al., 2010; Dungen et al.,
2011; Lainscak et al., 2011; Etminan et al., 2012; Loth et al.,
2014; Morales et al., 2014, 2017; Kubota et al., 2015; Baker
and Wilcox, 2017; Sessa et al., 2017a) despite aforementioned
studies evaluated different clinical outcomes and used different
follow-up periods (Salpeter et al., 2002; Hawkins et al., 2009;
Jabbour et al., 2010; Dungen et al., 2011; Lainscak et al., 2011;
Etminan et al., 2012; Kubota et al., 2015; Ponikowski et al.,
2016; Sessa et al., 2017a). Despite being unable to provide any
causal explanation for our results, we believe that the clinical
management of these patients may have played a key role in
our findings. In fact, while in the start of the beta-blocker
treatment patients tends to be highly monitored because of
the higher risk of bronchoconstriction, in the later phases
patients tend to be less strictly monitored (Gottlieb et al., 2002;
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Basile, 2003; Fonarow et al., 2008; Schimmer et al., 2009).
Therefore, if in the later phases of beta-blocker treatment
patients experienced worsening of the lung function it will
not necessarily lead to an immediate modulation of the beta-
blocker dosage which in turn potentially might happen at the
next healthcare contact (Fonarow et al., 2008). Consequently,
a sub-clinical effect of beta-blockade on the respiratory system
summed with an ongoing exacerbation of the respiratory disease
may results in a synergic negative effect in terms of respiratory
symptomatology, which could result intolerable for patients and
culminate in a hospitalization or beta-blocker discontinuation.
A plausible explanation for why we observed an increased risk
of heart failure hospitalization could be related to the prolonged
β2-adrenoreceptor antagonism performed by beta-blockers
less selective for β1-adrenoreceptor receptors. In particular
carvedilol, as recently proved in clinical settings, can alter
pulmonary compliance leading to dynamic hyperinflation even
in presence of β2-adrenoreceptor agonists and corticosteroids
(Jabbal and Lipworth, 2018). Dynamic hyperinflation, in turn,
apart from negative respiratory outcomes, can promote impaired
ventricular filling and low cardiac output along with a reduction
of intrathoracic blood volume and pulmonary vein dimensions,
all phenomenon that can promote decompensation of heart
failure (O’Donnell et al., 2015) From clinical and public health
perspectives, whenever confirmed with further evidence, this
study opens new possibilities for improving the prognosis
of beta-blocker treated patients with concurrent COPD or
asthma, and to minimize the burden associated with their
clinical management. We estimated that just by switching from
carvedilol to metoprolol/bisoprolol/nebivolol it was theoretically
possible to reduce 106 cases (95%CI 76–134) of heart failure
hospitalization and 131 cases (95%CI 62–201) of beta-blocker
discontinuation per 10,000 person-years of observational period.
There is unfortunately only a speculative explanation of the
results. The observation would benefit for additional data to
investigate why increase hospitalization for heart failure, but not
COPD is caused by the use of non-selective beta-blockers.
Strengths and Limitations
Despite promising, our results should be considered in virtue of
a set of limitations. The first is related to data sources. Caserta
Local Health Unit administrative databases include information
on drugs redemption and hospitalization occurred in in the
catchment area of Caserta. Despite poorly likelihood, if a patient
redeemed a prescription or if the person was hospitalized
outside this area, the information is potentially lost. The second
limitation is the limited access to historical data. We had less
than a decade of observation period for our cohorts that do not
permit the determination of the first hospitalization for a certain
diagnosis (such as heart failure, asthma and COPD). In fact, we
did not have the chance to assess for patients, the first date of beta-
blocker administration and the date of their first hospitalization
for heart failure or COPD. The third limitation is the lacking
of indication of use for redeemed drugs that do not exclude the
misclassification of some patients in our study population. In an
example, it could not be ruled out that the indication of use of R03
drugs was for asthma instead of COPD. On the other hand, the
major strengths of this study are the sample size, the long follow-
up period, and inclusion of the entire population of Caserta
minimizing the risk of selection biases. Moreover, the possibility
of relying on real-world data from routine clinical practice which
provide “evidence” that may directly support changes in clinical
practice and policy decisions, especially in Caserta Local Health
Unit (Romio et al., 2013).
CONCLUSION
In the present study, patients with heart failure and concurrent
respiratory disease were followed for 5 years. Carvedilol,
a non-selective beta-adrenoreceptor blocker, was associated
with an increased risk of discontinuation if compared to
metoprolol, bisoprolol or nebivolol. Moreover, it was associated
with an increased risk of heart failure hospitalization.
We estimated that just by switching from carvedilol to
metoprolol/bisoprolol/nebivolol it was theoretically possible
to reduce heart failure hospitalization and beta-blocker
discontinuation.
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